Pacira BioSciences (PCRX) Investor presentation summary

Strategic transformation and financial performance

• Underwent significant transformation with new leadership, launching the 5x30 strategy to drive growth and value creation, achieving record 2025 revenues of $726.4M and non-GAAP gross margins of 81.2%—the highest in company history.

• Accelerated EXPAREL volume growth to 8% in 2H25, driven by commercial strategy and NOPAIN Act, with a five-percentage point non-GAAP gross margin improvement targeted by 2030.

• Diversified pipeline through GQ Bio acquisition (PCRX-201), in-licensing PCRX-2002, and strategic partnerships with Johnson & Johnson MedTech and LG Chem.

• Returned $200M to stockholders since April 2025 via share repurchases, with $100M remaining authorized.

• Strengthened EXPAREL’s patent estate to 21 Orange Book-listed patents, securing exclusivity through 2030 and favorable litigation settlement.

Growth drivers and pipeline advancement

• 5x30 plan targets treating over 3M patients annually, double-digit revenue CAGR, five-point margin improvement, five novel pipeline programs, and five partnerships by 2030.

• Q1 2026 revenue grew 5% YoY to $177M, with EXPAREL, ZILRETTA, and iovera all contributing; non-GAAP gross margin reached 80%.

• Pipeline includes two Phase 2 programs: PCRX-201 (gene therapy for knee OA, RMAT and PRIME designations) and PCRX-2002 (novel hydrogel for postsurgical pain), with additional preclinical assets.

• Strategic partnerships expand commercial reach and pipeline value, including J&J MedTech for ZILRETTA and LG Chem for EXPAREL in Asia-Pacific.

Board refreshment and governance

• Board refreshed with five new independent directors since October 2023 and a sixth nominated for 2026; 89% of directors will be independent post-2026 meeting.

• Board and management bring deep biopharma, executive, M&A, R&D, and commercialization expertise, critical for executing the 5x30 strategy.

• Compensation program emphasizes at-risk, performance-based incentives, with recent changes increasing alignment with stockholder interests.

• Strong governance practices include separation of Chair and CEO roles, annual board evaluations, and robust risk oversight.